AAN 2024: CAR-T therapy CAR-T initially developed as treatment option in cancer, but is now set to enter the MS domain to target autoreactive immune cells. This type of therapy is a world apart from our usual immunotherapies available in MS and require experienced neuroimmunologists to manage their unique side effects. Time and again I have seen comments on […]
https://multiple-sclerosis-res....earch.org/2024/04/aa